Targeting the IGF-1 axis may overcome ADT or docetaxel resistance and improve the outcome of patients with advanced PCa because both IGF-1 levels and IGF-1R expression are largely unaffected by castration or docetaxel treatment [58]. The gene discussed is IGF1R; the disease is posterior cortical atrophy.